Table 2 Comparisons in clinical outcome measures between type 2 diabetes mellitus group and control group after propensity score matching

Primary Outcomes

NRS leg/10

 Baseline

6.2 ± 1.9 (5.9-7.0)

6.3 ± 2.1 (6.4–7.3)

 6 weeks

5.0 ± 1.7 (4.4–5.6)

4.2 ± 1.6 (3.6–4.6)

< 0.001

0.023

< 0.001

 12 weeks

4.6 ± 1.9 (4.1–5.3)

3.7 ± 1.6 (3.0–4.0)

ODI /100

 Baseline

35.2 ± 12.1 (32.9–41.4)

35.7 ± 13.9 (31.9–41.0)

 6 weeks

33.5 ± 10.2 (33.1–38.6)

34.6 ± 15.5 (29.4–38.6)

0.010

0.397

0.774

 12 weeks

31.6 ± 9.9 (29.3–36.7)

33.0 ± 15.3 (27.8–36.8)

Second Outcomes

NRS back/10

 Baseline

3.9 ± 1.8 (3.3–4.6)

3.8 ± 1.2 (2.8–3.7)

0.031

0.155

0.122

 6 weeks

2.9 ± 1.7 (2.3–3.4)

2.2 ± 1.2 (1.8–2.6)

 12 weeks

2.3 ± 1.2 (1.9–2.7)

1.9 ± 1.0 (1.6–2.2)

SPWT

 Baseline

464.4 ± 221.4 (379.6–537.0)

462.1 ± 268.1 (351.3-529.7)

 6 weeks

545.3 ± 178.2 (478.0-612.7)

651.4 ± 246.0 (544.0-706.3)

< 0.001

0.042

0.027

 12 weeks

612.7 ± 189.1 (552.3-682.3)

776.5 ± 269.3 (642.1-823.8)

SF-36 BP /100

 Baseline

42.1 ± 13.0 (38.1–46.5)

42.2 ± 15.8 (37.6–48)

 6 weeks

47.6 ± 12.2 (43.8–51.5)

48.2 ± 16.0 (43.2–53.3)

0.363

0.134

0.291

 12 weeks

49.4 ± 11.6 (45.7–53.1)

52.5 ± 16.2 (47.4–57.6)

SF-36 PF/100

 Baseline

45.2 ± 12.8 (40.1–48.6)

46.3 ± 14.9 (42.8–52.0)

 6 weeks

47.1 ± 13.8 (42.7–51.4)

50.0 ± 14.7 (45.3–54.6)

0.247

0.182

0.121

 12 weeks

49.9 ± 13.5 (45.7–54.2)

53.7 ± 15.3 (48.9–58.6)

SBI/24

 Baseline

12.4 ± 4.1 (11.2–12.9)

11.5 ± 4.2 (10.4–13.2)

 6 weeks

9.5 ± 3.8 (8.3–0.7)

8.7 ± 4.7 (7.3–10.2)

0.032

0.098

0.166

 12 weeks

8.0 ± 3.8 (6.8–9.2)

6.7 ± 3.3 (5.7–7.8)

TSK-11/68

 Baseline

44.2 ± 9.2 (40.7–46.0)

44.8 ± 14.2 (37.7–45)

 6 weeks

41.0 ± 7.8 (38.5–43.4)

38.3 ± 11.9 (34.6–42.1)

0.128

0.144

0.453

 12 weeks

39.6 ± 7.7 (37.2–42.0)

36.8 ± 12.7 (32.8–40.8)

BDI/63

 Baseline

7.2 ± 3.6 (6.3–8.7)

7.0 ± 4.3 (4.6 to 7.2)

 6 weeks

5.9 ± 4.0 (4.5–6.9)

5.7 ± 4.3 (4.1 to 6.3)

0.087

0.106

0.051

 12 weeks

5.3 ± 3.6 (4.3–6.6)

5.0 ± 3.9 (3.8 to 6.2)